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BACKGROUND: Recent studies showed a significant upregulation of distinct microRNAs (miRNAs) in papillary thyroid carcinoma (PTC).
The objective of this study was to explore whether this upregulation could also be assigned to distinct histomorphological variants of
PTC, especially the follicular variant and other encapsulated follicular thyroid tumours.
METHODS: We used total RNA of 113 formalin-fixed paraffin-embedded tissues of 50 PTCs ((10 conventional type (PTC-CT), 10 tall
cell variants (PTC-TCVs), 30 follicular variants (PTC-FVs)), 10 follicular adenomas (FAs), 10 multinodular goitres (MNGs), 21 follicular
thyroid carcinomas and 22 well-differentiated tumours of unknown malignant potential (WDT-UMP) to analyse the miRNA
expression pattern of five selected miRNAs (146b, 181b, 21, 221 and 222) using RT–PCR TaqMan miRNA assay to explore the
diagnostic utility of this method.
RESULTS: The mean values of the expression pattern of all miRNAS in PTCs show a statistically significant difference from those in
MNG and FA with fold changes up to 90 for miRNA 146b, Po0.001. No differences in expression pattern could be showed between
MNG and FA. The PTC-FVs differ significantly from FA in all five miRNAS, from MNG in three and from WDT-UMP in one miRNA
with fold changes between 1.7 and 21.2, but failed to be of diagnostic value regarding individual cases with substantial overlaps.
CONCLUSION: We conclude that analysis of a set of five selected miRNAS distinguish common variants of PTC from FA/MNG but
failed to be a useful diagnostic method in individual and doubtful cases, especially in the differential diagnosis of encapsulated follicular
thyroid tumours.
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Papillary thyroid carcinomas (PTCs) represent the most common
thyroid malignancy; its diagnosis is based on the demonstration of
characteristic nuclear features such as enlargement, overlapping,
irregularity of nuclear contours, ground glass nuclei, grooves and
pseudoinclusions (Rosai et al, 1992; DeLellis and Williams, 2004).
However, PTCs comprise a morphologically heterogeneous group
covering distinct variants that are classified on the basis of the
occurrence of predominantly papillary structures (conventional
type (PTC-CT)), a distinct growth pattern (follicular variant (PTC-
FV) or cell type (e.g., tall cell variant (PTC-TCV)), among other
features (DeLellis and Williams, 2004; LiVolsi and Baloch, 2004).
This heterogeneity is also reflected in variable prevalences of the
three most common genetic alterations, RET/PTC rearrangements
(Nikiforov et al, 1997; Adeniran et al, 2006), BRAF (Trovisco et al,
2004; Xing, 2005) and RAS mutations (Vasko et al, 2003; Castro
et al, 2006) that can be shown in approximately 70% of all PTCs
(Nikiforova et al, 2008).
Since its original description by Crile and Hazard (1953) in 1953
and confirmation by Lindsay in 1960 (Lindsay, 1960) the PTC-FV
represents a diagnostic challenge (Lloyd et al, 2004). Differential
diagnostic problems are caused by the encapsulated form of PTC-
FV that essentially has to be distinguished from other encapsulated
lesions. With regard to therapeutic consequences, it is more
important to differ PTC-FV from follicular adenoma (FA) than
PTC-FV from minimally invasive follicular thyroid carcinoma
(FTC). Moreover, pathologists are frequently faced with encapsu-
lated thyroid tumours having ‘questionable’ PTC-type nuclear
changes, as it has been pointed out by Rosai, (2005). Those
tumours are referred to as ‘well-differentiated tumours of
uncertain malignant potential’ (WDT-UMP) in the literature.
MicroRNAs (miRNAs) are endogenous, non-coding, small RNAs
that regulate gene expression. A large number of miRNAs are
involved in almost every major cellular function (Cowland et al,
2007) and as a consequence, deregulation of miRNAs has also been
linked to a broad variety of cancers (Calin et al, 2002, 2005;
Michael et al, 2003; Takamizawa et al, 2004; Iorio et al, 2005;
Lu et al, 2005; Mattie et al, 2006; Murakami et al, 2006; Volinia
et al, 2006). Recently, a few studies reported on deregulated
miRNAs in PTC using miRNA microarrays (He et al, 2005; Pallante
et al, 2006; Tetzlaff et al, 2007; Nikiforova et al, 2008) and
Received 4 September 2009; revised 18 November 2009; accepted 20
November 2009; published online 22 December 2009
*Correspondence: Dr KW Schmid, Institute of Pathology and Neuro-
pathology, University Hospital of Essen, University of Duisburg-Essen,
Hufelandstr. 55, 45122 Essen, Germany;
E-mail: kw.schmid@uk-essen.de
3Member of the West German Cancer Centre Essen (WTZE), Essen,
Germany.
British Journal of Cancer (2010) 102, 376–382
& 2010 Cancer Research UK All rights reserved 0007– 0920/10 $32.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sRT–PCR TaqMan miRNA assay (Tetzlaff et al, 2007; Chen et al,
2008; Nikiforova et al, 2008), identifying a limited number of
miRNAs that are significantly upregulated in PTC compared with
normal thyroid tissue (He et al, 2005; Pallante et al, 2006; Chen
et al, 2008; Nikiforova et al, 2008), hyperplastic nodules (Chen
et al, 2008; Nikiforova et al, 2008) and multinodular goitre
(Tetzlaff et al, 2007; for review, see Table 1), suggesting miRNA
analysis as a promising tool in diagnostic thyroid pathology.
With regard to both the morphologic and genetic differences
between PTC variants, we asked whether analysis of a distinct set
of miRNAs is able to reliably distinguish common variants of
PTC (PTC-CT, PTC-TCV and PTC-FV) from multinodular goitre
(MNG) and FA and whether miRNA expression profiling is a
useful tool in the differential diagnosis of encapsulated follicular
thyroid tumours.
MATERIALS AND METHODS
Patients and tumour samples
For this study we selected the following cases from the files of the
Institute of Pathology and Neuropathology, University Hospital of
Essen, Germany: 10 cases with an (almost) exclusive papillary
architecture, the characteristic nuclear features outlined by the
WHO classification (2004), and particularly lacking both the
cellular and nuclear features of the tall cell variant of PTC that
belong to the conventional-type group (PTC-CT). Another 10 cases
were categorised as the tall cell variant of PTC (PTC-TCV). These
tumours showed tumour cells at least twice high than wide with an
abundant eosinophilic cytoplasm and typical nuclear character-
istics, including eosinophilic pseudoinclusions. To explore differ-
ences in miRNA expression, especially in encapsulated follicular
thyroid tumours, we selected 30 cases composed of 495% of
follicular structures and characteristic nuclear features corres-
ponding to the follicular variant of PTC (PTC-FV). Out of
50 PTCs, seven had been previously analysed for miRNA analysis
(Schwertheim et al, 2009; Sheu et al, 2009). A total of
21 minimally invasive FTCs with either capsular (n¼6) or vascular
invasion (n¼13) or both (n¼2) were also included. In addition,
we selected 22 encapsulated follicular tumours with questionable
nuclear changes without vascular/capsular invasion; these tumours
are categorised as WDT-UMP. A total of 10 encapsulated thyroid
FAs and 10 MNGs were also included. All patients gave informed
consent and the study was strictly performed according to the
Declaration of Helsinki.
Table 1 Literature review over miRNA quantitative RT–PCR studies in thyroid tumours
Material, Total sample Tumour type/normal thyroid Deregulated miRNA Reference
Fresh-frozen tissue, n¼10 Matched pairs of 5 PTCs and 5
normal thyroids
miRNAs 221, 222 and 146b upregulated in PTC vs normal
thyroid
He et al (2005)
Snap-frozen tissue, n¼9 5 FTCs
4, FAs
4, normal thyroids
miRNAs 197 and 56 upregulated in FTC vs FA Weber et al (2006)
Fresh frozen tissue, n¼47 8 FAs and
39 PTCs
Precursor miRNAs 221, 222 and 181b-1 upregulated in
PTC vs FA
Pallante et al (2006)
Formalin-fixed paraffin-
embedded tissue, n¼20
10 PTCs (conventional variant) and
10 MNGs
miRNAs 21, 31, 221 and 222 upregulated in PTC vs MNG Tetzlaff et al (2007)
Fresh-frozen and formalin-
fixed paraffin-embedded
tissue, n¼20
20 ATCs miRNAs 30d, 125b, 26 and 30-a-5p downregulated in ATC
vs normal thyroid
Visone et al (2007)
Snap-frozen tissue, n¼60 23 PTCs (18 conventional and
5 follicular variants)
9 FTCs,
8 FAs,
4A C s ,
4 PDCs,
2 MCs,
5 normal thyroids and
5 hyperplastic nodules
miRNAs 187, 221, 222, 181b, 146b, 155 and 224
upregulated in follicular cell-derived carcinomas with high
variance between tumour type; miRNAs 187, 221, 222,
146b and 155 upregulated in PTC with strong relationship
to mutational status
Nikiforova et al (2008)
Formalin-fixed paraffin-
embedded tissue, n¼74
32 PTCs (27 conventional and
5 follicular variants)
24 FAs,
10 ‘borderline’ follicular lesions,
11 hyperplastic nodules,
2 FTCs and
5 normal thyroid
miRNA 146 upregulated in PTC vs non-papillary
carcinomas; miRNAs 221 and 222 upregulated in PTC vs
FA, hyperplastic nodules, normal thyroid but with
substantial overlaps in individual cases; miRNA 146b
indistinguishable between ‘borderline’ tumours and FA and
lower than in PTC
Chen et al (2008)
Formalin-fixed paraffin-
embedded tissue, n¼113
50 PTCs (10 conventional, 10 tall
cell and 30 follicular variants)
22 WDT-UMPs,
21 FTCs
10 FAs and
10 MNGs
Mean values of miRNAs 146b, 181b, 21, 221 and 222
upregulated in PTC; miRNA 146b upregulated in PTC-CT/
PTC-TCV vs MNG/FA; substantial overlaps of all miRNAs
in follicular cell-derived tumours; intermediate miRNA
expression profile of PTC-FV
Our study
Abbreviations: PTC¼papillary thyroid carcinoma; FTC¼follicular thyroid carcinoma; FA¼follicular adenoma; MNG¼multinodular goitre; ATC/AC¼anaplastic carcinoma;
PDC¼poorly differentiated carcinoma; MC¼medullary carcinoma; WDT-UMP¼well-differentiated tumour of unknown malignant potential.
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Macrodissection from paraffin-embedded specimens to obtain
‘pure’ tumour tissues was performed as described before
(Sheu et al, 2007). From all cases, at least three tissue blocks were
available and ‘morphologic homogeneity’, especially in variants of
PTC, was proven in all blocks. Clinicopathologic data of all cases
are summarised in Table 2.
RNA extraction
RNA was extracted using the RNeasy FFPE Kit (Qiagen, Hilden,
Germany). In brief, tissue sections were deparaffinised by xylene/
ethanol treatment. Tissue pellets were resuspended in 150ml buffer
PKD, 20ml proteinase K and incubated overnight on a shaker
incubator at 561C. Further processing of the samples was
performed according to the recommendations of the supplier.
Selection and detection of miRNAs
For this study we selected a set of five miRNAs (miRNAs 146b,
181b, 21, 221 and 222) that are significantly upregulated in PTC
compared with normal thyroid tissue (He et al, 2005; Pallante et al,
2006; Nikiforova et al, 2008), hyperplastic nodules (Nikiforova
et al, 2008) and multinodular goiter (Tetzlaff et al, 2007). This set
of miRNAs was analysed using the real-time RT–PCR scheme for
miRNA quantification according to the protocol of Applied
Biosystems (P/N: 4364031); this two-step protocol consists of
reverse transcription with a miRNA-specific primer, followed by
real-time PCR with TaqMan probes. The TaqMan miRNA assays
used were also provided by Applied Biosystems. In brief, for each
RT–PCR 50ng RNA was reverse transcripted to cDNA using 3ml
specific looped RT primers (Applied Biosystems, Darmstadt,
Germany and 200U MuLV reverse transcriptase (Fermantas,
Vilnius, Lithuania). The 15ml reactions were incubated in a
Primus 25 thermocycler (MWG Biotech, Ebersberg, Germany) for
30min at 161C, 30min at 421C, 5min at 851C and then kept at
41C. Real-time PCR was performed in triplicate using a standard
protocol on the Applied Biosystems 7500 Sequence Detection
System. Each PCR included 5.25ml of a 1:25 dilution of specific
cDNA in water, 1ml of the specific miRNA Assay Mix and 6.25mlo f
2  Taq Man Universal PCR Master Mix. The reactions were
incubated in a 96-well plate at 951C for 10min, followed by 40
cycles at 951C for 15s and 601C for 1min. In each sample the
relative amount of miRNA was calculated using the comparative
threshold method determining RNU 48 as the endogenous control
with DCt¼Ct (miRNA) – Ct (RNU48). Relative quantification of
miRNA expression was calculated with the 2
 DDCt method
(Applied Biosystems user bulletin no. 2 (P/N 4303859)). This
method facilitates detecting and quantifies exclusively mature
miRNAs but not their precursors.
Statistical analysis
Statistical analysis was performed using the Statistical package for
Social Sciences (SPSS; Version 17.0 for Windows, Chicago, IL,
USA). Correlations between different mean DCt values and relative
quantification of miRNA expression were assessed using the
Mann–Whitney test for two unpaired groups.
RESULTS
miRNA expression patterns in all PTC vs benign thyroid
lesions (FA and MNG)
Comparison of mean DCt values of PTC as a group, including all
variants, and FA and MNG, respectively, show a statistically
significant difference in the expression pattern of all miRNAs
(Pp0.012) with lower mean values in all PTC samples analysed
(Table 3). Calculating relative changes in gene expression by the
2
 DDCt method (Livak and Schmittgen, 2001) showed a 80- to
90-fold change of miRNA 146b in all PTC cases (Po0.001; Table 3)
for both groups (PTC vs MNG and PTC vs FA). Fold changes
varied between 0.8 and 16.4 for the other miRNAs tested. All five
miRNAs that were analysed lacked significant differences between
MNG and FA.
miRNA expression pattern in variants of PTC
The miRNA patterns of different variants of PTC are depicted in
Figure 1. Whereas PTC-CT and PTC-TCV did not differ
significantly in mean DCt values and consecutively fold changes
of gene expression for all types of miRNA, the miRNA patterns of
both PTC-CT and PTC-TCV differed from PTC-FV. When
comparing mean values of PTC-CT and PTC-FV, a significant
difference was exclusively found for miRNA 146b (fold change 8.0;
P¼0.043). Mean DCt values of PTC-TCV differed significantly
from PTC-FV in three miRNAs (146b, 21 and 222; Po0.028) that
correspond to fold changes between 2.9 and 9.9.
Regarding individual cases of PTC-FV, we observed a broad
variability in every miRNA analysed. This variability covered the
whole range of DCt values of benign (MNG and FA) and also TCV
and CT of PTC. However, there was no overlap between every
Table 2 Clinicopathological features of all cases
No. of cases Male/female ratio Mean age (year)±s.d. Mean tumour size (mm)±s.d.
All samples 113 1:2.8 46.6±15.2 27.3±14.8
Diagnosis
MNG 10 1:4 49.5±10.1
FA 10 1.5:1 46.7±10.3 25.4±11.5
PTC 50 1:2.8 49.2±15.2 27.3±17.1
Conventional 10 1:4 48.1±14.0 26.2±18.8
Tall cell 10 1:9 58.6±12.7 24.9±13.5
Follicular 30 1:2 46.4±15.4 28.5±18.1
FTC with 21 1:9.5 44.3±18.3 27.5±13.5
Vascular invasion 13
Capsular invasion 6
Both 2
WDT-UMP 22 1:2.1 41.3±15.5 27.7±11.8
Abbreviations: MNG¼multinodular goitre, FA¼follicular adenoma, PTC¼papillary thyroid carcinoma, FTC¼follicular thyroid carcinoma, WDT-UMP¼well-differentiated
tumour of unknown malignant potential.
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146b is the only miRNA to reliably discriminate between PTC
(conventional and tall cell variant) and benign thyroid lesions.
Minimal overlaps exist concerning miRNA 221 and 222 in single
cases that do not qualify these types to reliably distinguish between
these two variants of PTC and MNG/FA.
miRNA expression pattern in encapsulated follicular
tumours
Taking out PTC-FV as a group, we looked for differences in
expression pattern compared with benign thyroid lesions (Fig. 1
and Table 4). As it could already be observed for all PTCs (Table 3)
the follicular variant also showed significant differences in mean
DCt values in at least three of five examined miRNA types
compared with FA and MNG. Only miRNA 146b was upregulated
when comparing mean values of PTC-FV with WDT-UMP and
FTC. Surprisingly, mean values of miRNA 146b and 21 differed in
FA compared with FTC (Pp0.004), whereas only miRNA 21
showed a fold change of 3.0 between WDT-UMP and FTC
(P¼0.027). Regarding miRNA deregulation in individual cases
of PTC-FV there was also a broad overlap within all analysed
encapsulated thyroid tumours whether they showed partial nuclear
features of PTC (WDT-UMP) or not (FTC).
DISCUSSION
In accordance with previous studies (He et al, 2005; Pallante et al,
2006; Tetzlaff et al, 2007; Chen et al, 2008; Nikiforova et al, 2008)
the analysis of a limited set of miRNAs represents a reliable
method to distinguish PTC from benign thyroid lesions (for review
see Table 1). Considering the mean DCt values of all miRNAs
analysed in our study, we showed highly significant changes
between PTC and MNG/FA. However, the most common variants
of PTC show a different miRNA expression pattern with similar
profiles of PTC-CT and PTC-TCV in contrast to the follicular
variant of PTC. As for diagnostic purposes, only miRNA 146b
reliably distinguish the conventional and tall cell variant from
benign thyroid lesions in individual cases, whereas all other
miRNAs show substantial overlap. This is in accordance with a
study by Chen et al (2008) who found miRNA 146b to be most
consistently overexpressed in both conventional and follicular
variants when compared with ‘borderline’ follicular lesions,
although the number of five follicular variants in their study is
rather small.
The functional relevance of overexpressed miRNA 146b and its
effect on PTC tumourigenesis had been elucidated in two studies
(Taganov et al, 2006; Jazdzewski et al, 2008) so far. Taganov et al,
(2006) identified TNF receptor-associated factor 6 (TRAF6) and
IL-1 receptor-associated kinase (IRAK1), which represent potential
molecular targets of miRNA 146, as modulating the immune
response in a NF-kB-dependent manner. As far as NF-kB is one of
the key factors controlling anti-apoptotic response in thyroid cells,
it is also modulated by activated MAPK (Namba et al, 2007) in
PTC. This pathway, in turn, is involved in downstream effects of
RET/PTC rearrangements, RAS and BRAF mutations, the latter
being most frequently verifiable in PTC. Therefore, it seems not
surprising that upregulation of miRNA 146 is more distinctive in
the conventional and tall cell variant of PTC, as these variants are
significantly associated with the common V600E BRAF mutation.
However, in a previous study we asked for a possible correlation
between the occurrence of V600E BRAF mutation and miRNA
expression profile and found no significant differences in miRNA
expression between PTC harbouring the BRAF mutation and wild-
type BRAF, implicating that this mutation has no regulatory
influence on the expression pattern of these 5 miRNAs (Sheu
et al, 2009). Our results are in contrast to another study by
Nikiforova et al (2008) who founded a strong relationship between
miRNA expression and mutational status (BRAF, RET/PTC and
PAX8-PPARg). The reported differences might be due to the
variable number of tissue samples (28 vs 6) harbouring V600E
mutation and probably different statistical analysis and illustration
(raw data presenting DCt values vs principal component analysis
(PCA)). This possible relationship should be validated in a larger
cohort of PTCs.
The miRNA pattern of PTC-FV in this study differed from PTC-
TCV in three (miRNAs 146b, 21 and 222) and from PTC-CT in 1
miRNA (miRNA 146b). In our previous study (Sheu et al, 2009)
we normalised fold changes in PTC variants to adjacent normal
thyroid tissue in a pairwise manner and found that follicular
variants showed 3/5 upregulated miRNAs (146b, 221 and 222),
whereas the conventional type differed in 4/5 (146b, 181b, 221, and
222) and tall cells in all examined miRNAs, indicating a hetero-
geneous regulatory role of certain miRNAs within PTCs. Although
PTCs as a group of tumours sharing cytologic similarities showed a
distinct upregulated miRNA pattern, differences in various genetic
alterations among PTC variants are quite common. The V600E
BRAF mutation has been shown in approximately 43% of PTC
(Lupi et al, 2007), ranging from 12% in PTC-FV to 77% in PTC-
TCV (Xing, 2005). Interestingly, a distinct BRAF mutation (K601E)
had been exclusively found in PTC-FV (Trovisco et al, 2004, 2005)
Table 3 Mean DCt values and fold changes in PTC, MNG and FA
PTC
a vs MNG PTC
a vs FA MNG vs FA
miRNA type Tumour tissue Mean DCt Fold change P-value Fold change P-value Fold change P-value
146b MNG 5.922
FA 6.092 81.3 o0.001 91.4 o0.001 1.1 NS
PTC
a  0.422
181b MNG 2.239
FA 1.986 2.1 0.012 1.7 0.003 0.8 NS
PTC
a 1.200
21 MNG 4.159
FA 4.338 4.4 0.001 4.9 o0.001 1.1 NS
PTC
a 2.032
221 MNG 5.835
FA 6.289 9.4 0.002 12.9 0.001 1.4 NS
PTC
a 2.605
222 MNG 3.183
FA 3.992 9.4 0.001 16.4 o0.001 1.8 NS
PTC
a  0.044
aPTC includes all variants of PTC (conventional type, tall cell variant and follicular variant).
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of PTC-FV is also supported by the results of Castro et al (2006)
who found similar frequencies of activating point mutations of the
RAS genes and PAX8-PPARg rearrangement in PTC-FV, FA and
FTC; both genetic alterations are absent (PAX8-PPARg; Kroll et al,
2000; Nikiforova et al, 2002) or exceedingly rarely (RAS; Vasko
et al, 2003) found in ‘non follicular variant’ of PTC.
However, the comparison of miRNA expression profile of PTC-
FV and other encapsulated follicular thyroid lesions revealed a
broad variability among individual cases with substantial overlap.
We observed a similar broad DCt range especially in PTC-FV and
WDT-UMPs, reflecting that both tumours not only share distinct
morphologic characteristics but also similarities in miRNA
regulation. As for practical purposes, the determination of miRNA
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Figure 1 Different miRNA expression profiles of PTC variants, encapsulated benign and malignant lesions. Only miRNA 146b distinguishes every
single PTC-TCV and PTC-CT from MNG and FA (A) whereas miRNAs 221 (D) and 222 (E) showed remarkable differences as well but failed to be a
reliable diagnostic tool. PTC-FV and WDT-UMP revealed a broad variability in every type of miRNA analysed, covering the whole miRNA expression range
that do not allow a clear distinction among tumour types. Mean values of miRNAs 146b and 21 differ significantly between FA and FTC in miRNA 21
(P¼0.004; Po0.001).
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clarify the biological significance of those tumours assuming that
there might be other factors than the characteristic nuclear
features in the ‘majority of the tumour’ of PTC-FV as outlined in
the WHO classification. Regarding clinical and therapeutical
consequences, especially the discrimination between FA and
PTC-FV and FA vs FTC, respectively, the miRNA expression
analysis also failed to be of diagnostic value, although highly
significant mean DCt values and consecutively fold changes up to
approximately 21 (for 146b) between PTC-FV and FA indicate
remarkable differences. However, these changes could only be
showed in mean values but not in individual cases. Surprisingly
and in addition to the identified miRNAs (197, 328, 346 and 192)
by Weber (Weber et al, 2006) we found differences in miRNA
expression pattern between FA and FTC with fold changes between
3.1 and 3.5 for miRNAs 146b and 21, and in accordance with their
study, not for miRNAs 221 and 221, indicating the latter two being
essentially involved in PTC pathogenesis, as it has previously been
shown by Pallante (Pallante et al, 2006). This points towards the
role of miRNA 146b as being generally involved in both (papillary
and follicular) phenotypes of thyroid carcinogenesis, reflecting
other genetic alterations that partly result in characteristic nuclear
features. In our study, and as for the distinction between FA and
FTC, miRNA 21 seem to have a regulatory role, as an upregulation
of miRNA could recently be shown in RAS-transformed FRTL-5
thyroid cells (Talotta et al, 2009). Two targets of miRNA 21, the
tumour suppressor genes PTEN and PDCD4, are downregulated in
a novel autoregulatory loop mediated by miRNA 21 through the
transcription factor AP1 in response to RAS, thus indicating a
tumourigenetic role for miRNA, but they failed to be of diagnostic
value in every single case in our study.
We have shown that an analysis of a set of five selected miRNAs
distinguish common variants of PTC from follicular adenoma and
multinodular goitre but failed to be a useful diagnostic method in
individual and doubtful cases, especially in the differential
diagnosis of follicular thyroid tumours (PTC-FV, FA, WDT-UMP
and FTC). In addition, miRNA expression profiling confirms the
so far ‘intermediate’ position of PTC-FV between conventional and
tall cell variants of PTCs on one hand, and on the other hand, the
follicular thyroid tumours with partly nuclear features of unknown
malignant potential and minimal invasive FTC.
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